STAA: financial statements from SEC — TradeAlmanac

STAA

STAAR Surgical Company: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	Dec 31, 2025	Dec 31, 2024
Revenue	239m	314m
Cost of revenue	57m	74m
Gross profit	182m	240m
Research and development	40m	45m
Selling, general and administrative	274m	252m
Operating income	−92m	−13m
Pre-tax income	−82m	−9m
Income tax	−2m	11m
Net income	−80m	−20m
Earnings per share	−1.62	−0.41
Earnings per share, diluted	−1.62	−0.41
Weighted average shares	50m	49m
Weighted average shares, diluted	50m	49m

Balance sheet

Metric	Mar 31, 2026	Dec 31, 2025	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024
Cash and equivalents	132m	153m	176m	167m	173m	144m	164m	193m
Short-term investments	32m	34m

Cash flow

Metric	Dec 31, 2025	Dec 31, 2024
Operating cash flow	−34m	16m
Depreciation and amortisation	8m	7m
Share-based compensation	31m	27m
Capital expenditure	6m	23m
Investing cash flow	46m	−59m
Share buybacks	6m

Amounts in USD unless stated otherwise. Sources: Nasdaq Trader, Yahoo Finance, U.S. Securities and Exchange Commission (EDGAR)